Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial* - Prasse, A; Distler, O; Highland, KB; Gahlemann, M; Azuma, A; Mayes, MD; Raghu, G; Sauter, W; Girard, M; Alves, M; Clerisme-Beaty, E; Kuwana, M; Maher, TM (Pneumologie, 2020)